Once-weekly teriparatide in hemodialysis patients with hypoparathyroidism and low bone mass: a prospective study.

Sumida K, Ubara Y, Hoshino J, Mise K, Hayami N, Suwabe T, Kawada M, Imafuku A, Hiramatsu R, Hasegawa E, Yamanouchi M, Sawa N, Takaichi K

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA2 Nov 2015Cited by 60 (Europe PMC)

PMID26525045DOI10.1007/s00198-015-3377-6PepBankPUB-26525045

Publisher page PubMedAsk about this study

Jump to 11 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study11

10 results from studies that gave the peptide. 10 results from people.

01HumanObservational studyEfficacy outcome
In hemodialysis patients with hypoparathyroidism and low bone mass, teriparatide use was linked to increased lumbar spine BMD at 24 weeks.
In plain wordsIn hemodialysis patients with low bone mass, teriparatide use was linked to increased lumbar spine bone density at 24 weeks.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseLumbar spine BMD at 24 weeks
Study
n: not reported in source
Analysis
Primary
Outcome group
Bone and joint · Musculoskeletal
Studied dose
56.5 μg once weekly · 48 weeksAs given in this study (human).
Measurements
BMD change
3.3%
24 weeks
SEM
1.9%
24 weeks
Source sentences
Summary
The BMD increased at the lumbar spine by 3.3 ± 1.9 % (mean ± SEM) and 3.0 ± 1.8 % at 24 and 48 weeks but not in the femoral neck and distal one-third radius.
1 context sentence(design, population, supporting numbers)
Summary · context
We conducted a 48-week prospective, observational cohort study including 22 hemodialysis patients aged 20 years or older with hypoparathyroidism and low bone mass who received once-weekly teriparatide at 56.5 μg at a tertiary care hospital between January 2013 and January 2015.
Report a problemFND-2652504501
02HumanObservational studyEfficacy outcome
In hemodialysis patients with hypoparathyroidism and low bone mass, teriparatide use was linked to increased lumbar spine BMD at 48 weeks.
In plain wordsIn hemodialysis patients with low bone mass, teriparatide use was linked to increased lumbar spine bone density at 48 weeks.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseLumbar spine BMD at 48 weeks
Study
n: not reported in source
Analysis
Primary
Outcome group
Bone and joint · Musculoskeletal
Studied dose
56.5 μg once weekly · 48 weeksAs given in this study (human).
Measurements
BMD change
3%
48 weeks
SEM
1.8%
48 weeks
Source sentences
Summary
The BMD increased at the lumbar spine by 3.3 ± 1.9 % (mean ± SEM) and 3.0 ± 1.8 % at 24 and 48 weeks but not in the femoral neck and distal one-third radius.
1 context sentence(design, population, supporting numbers)
Summary · context
We conducted a 48-week prospective, observational cohort study including 22 hemodialysis patients aged 20 years or older with hypoparathyroidism and low bone mass who received once-weekly teriparatide at 56.5 μg at a tertiary care hospital between January 2013 and January 2015.
Report a problemFND-2652504502
03HumanObservational studyEfficacy outcome
In hemodialysis patients with hypoparathyroidism and low bone mass, femoral neck BMD did not increase during teriparatide treatment.
In plain wordsIn hemodialysis patients with low bone mass, femoral neck bone density did not increase during teriparatide treatment.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeFemoral neck BMD
Study
n: not reported in source
Analysis
Primary
Outcome group
Bone and joint · Musculoskeletal
Studied dose
56.5 μg once weekly · 48 weeksAs given in this study (human).
Source sentences
Summary
The BMD increased at the lumbar spine by 3.3 ± 1.9 % (mean ± SEM) and 3.0 ± 1.8 % at 24 and 48 weeks but not in the femoral neck and distal one-third radius.
1 context sentence(design, population, supporting numbers)
Summary · context
We conducted a 48-week prospective, observational cohort study including 22 hemodialysis patients aged 20 years or older with hypoparathyroidism and low bone mass who received once-weekly teriparatide at 56.5 μg at a tertiary care hospital between January 2013 and January 2015.
Report a problemFND-2652504503
04HumanObservational studyEfficacy outcome
In hemodialysis patients with hypoparathyroidism and low bone mass, distal one-third radius BMD did not increase during teriparatide treatment.
In plain wordsIn hemodialysis patients with low bone mass, distal radius bone density did not increase during teriparatide treatment.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeDistal one-third radius BMD
Study
n: not reported in source
Analysis
Primary
Outcome group
Bone and joint · Musculoskeletal
Studied dose
56.5 μg once weekly · 48 weeksAs given in this study (human).
Source sentences
Summary
The BMD increased at the lumbar spine by 3.3 ± 1.9 % (mean ± SEM) and 3.0 ± 1.8 % at 24 and 48 weeks but not in the femoral neck and distal one-third radius.
1 context sentence(design, population, supporting numbers)
Summary · context
We conducted a 48-week prospective, observational cohort study including 22 hemodialysis patients aged 20 years or older with hypoparathyroidism and low bone mass who received once-weekly teriparatide at 56.5 μg at a tertiary care hospital between January 2013 and January 2015.
Report a problemFND-2652504504
05HumanObservational studyEfficacy outcome
In hemodialysis patients, teriparatide use was linked to increased serum osteocalcin at 4 weeks, with higher concentrations maintained through 48 weeks.
In plain wordsIn hemodialysis patients, teriparatide use was linked to increased osteocalcin at 4 weeks, with higher levels maintained through 48 weeks.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseSerum osteocalcin
Study
n: not reported in source
Analysis
Secondary
Outcome group
Bone and joint · Musculoskeletal
Studied dose
56.5 μg once weekly · 48 weeksAs given in this study (human).
Source sentences
Summary
Serum osteocalcin, BAP, and P1NP increased significantly at 4 weeks, maintaining higher concentrations up to 48 weeks, although TRAP-5b decreased gradually during treatment.
1 context sentence(design, population, supporting numbers)
Summary · context
We conducted a 48-week prospective, observational cohort study including 22 hemodialysis patients aged 20 years or older with hypoparathyroidism and low bone mass who received once-weekly teriparatide at 56.5 μg at a tertiary care hospital between January 2013 and January 2015.
Report a problemFND-2652504505
06HumanObservational studyEfficacy outcome
In hemodialysis patients, teriparatide use was linked to increased BAP at 4 weeks, with higher concentrations maintained through 48 weeks.
In plain wordsIn hemodialysis patients, teriparatide use was linked to increased BAP at 4 weeks, with higher levels maintained through 48 weeks.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseSerum bone-specific alkaline phosphatase
Study
n: not reported in source
Analysis
Secondary
Outcome group
Bone and joint · Musculoskeletal
Studied dose
56.5 μg once weekly · 48 weeksAs given in this study (human).
Source sentences
Summary
Serum osteocalcin, BAP, and P1NP increased significantly at 4 weeks, maintaining higher concentrations up to 48 weeks, although TRAP-5b decreased gradually during treatment.
1 context sentence(design, population, supporting numbers)
Summary · context
We conducted a 48-week prospective, observational cohort study including 22 hemodialysis patients aged 20 years or older with hypoparathyroidism and low bone mass who received once-weekly teriparatide at 56.5 μg at a tertiary care hospital between January 2013 and January 2015.
Report a problemFND-2652504506
07HumanObservational studyEfficacy outcome
In hemodialysis patients, teriparatide use was linked to increased P1NP at 4 weeks, with higher concentrations maintained through 48 weeks.
In plain wordsIn hemodialysis patients, teriparatide use was linked to increased P1NP at 4 weeks, with higher levels maintained through 48 weeks.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseSerum P1NP
Study
n: not reported in source
Analysis
Secondary
Outcome group
Bone and joint · Musculoskeletal
Studied dose
56.5 μg once weekly · 48 weeksAs given in this study (human).
Source sentences
Summary
Serum osteocalcin, BAP, and P1NP increased significantly at 4 weeks, maintaining higher concentrations up to 48 weeks, although TRAP-5b decreased gradually during treatment.
1 context sentence(design, population, supporting numbers)
Summary · context
We conducted a 48-week prospective, observational cohort study including 22 hemodialysis patients aged 20 years or older with hypoparathyroidism and low bone mass who received once-weekly teriparatide at 56.5 μg at a tertiary care hospital between January 2013 and January 2015.
Report a problemFND-2652504507
08HumanObservational studyEfficacy outcome
In hemodialysis patients, TRAP-5b decreased gradually during teriparatide treatment.
In plain wordsIn hemodialysis patients, TRAP-5b decreased gradually during teriparatide treatment.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseSerum TRAP-5b
Study
n: not reported in source
Analysis
Secondary
Outcome group
Bone and joint · Musculoskeletal
Studied dose
56.5 μg once weekly · 48 weeksAs given in this study (human).
Source sentences
Summary
Serum osteocalcin, BAP, and P1NP increased significantly at 4 weeks, maintaining higher concentrations up to 48 weeks, although TRAP-5b decreased gradually during treatment.
1 context sentence(design, population, supporting numbers)
Summary · context
We conducted a 48-week prospective, observational cohort study including 22 hemodialysis patients aged 20 years or older with hypoparathyroidism and low bone mass who received once-weekly teriparatide at 56.5 μg at a tertiary care hospital between January 2013 and January 2015.
Report a problemFND-2652504508
09HumanObservational studySafety outcome
In hemodialysis patients receiving teriparatide, transient hypotension was the most common adverse event.
In plain wordsIn hemodialysis patients receiving teriparatide, transient low blood pressure was the most common adverse event.
Peptide
Teriparatide (PTH 1-34)
Outcome
Not applicableTransient hypotension
Study
n = 22
Outcome group
Adverse events · Cardiovascular
Studied dose
56.5 μg once weekly · 48 weeksAs given in this study (human).
Source sentences
Summary
Transient hypotension was the most common adverse event.
1 context sentence(design, population, supporting numbers)
Summary · context
We conducted a 48-week prospective, observational cohort study including 22 hemodialysis patients aged 20 years or older with hypoparathyroidism and low bone mass who received once-weekly teriparatide at 56.5 μg at a tertiary care hospital between January 2013 and January 2015.
Report a problemFND-2652504510
10HumanObservational studySafety outcome
In hemodialysis patients, ten patients discontinued teriparatide because of adverse events.
In plain wordsIn hemodialysis patients, ten patients stopped teriparatide because of adverse events.
Peptide
Teriparatide (PTH 1-34)
Outcome
Not applicableDiscontinuation because of adverse events
Study
n = 22
Outcome group
Adverse events · Whole body
Studied dose
56.5 μg once weekly · 48 weeksAs given in this study (human).
Measurements
Discontinuations
10 patients
adverse events
Source sentences
Summary
Ten patients discontinued treatment because of adverse events.
1 context sentence(design, population, supporting numbers)
Summary · context
We conducted a 48-week prospective, observational cohort study including 22 hemodialysis patients aged 20 years or older with hypoparathyroidism and low bone mass who received once-weekly teriparatide at 56.5 μg at a tertiary care hospital between January 2013 and January 2015.
Report a problemFND-2652504511

Studies that did not test the peptide alone1

In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Teriparatide (PTH 1-34).

11HumanNot a test of Teriparatide (PTH 1-34) aloneObservational studyOther
In hemodialysis patients receiving teriparatide, baseline BAP was linked to lumbar spine BMD percentage change at 48 weeks.
In plain wordsIn hemodialysis patients receiving teriparatide, baseline BAP was linked to lumbar spine bone density change at 48 weeks.
Peptide
Teriparatide (PTH 1-34)
Outcome
Direction not reportedBaseline BAP association with lumbar spine BMD response
Study
n: not reported in source
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
The baseline BAP was significantly associated with the 48-week percent change in lumbar spine BMD.
1 context sentence(design, population, supporting numbers)
Summary · context
We conducted a 48-week prospective, observational cohort study including 22 hemodialysis patients aged 20 years or older with hypoparathyroidism and low bone mass who received once-weekly teriparatide at 56.5 μg at a tertiary care hospital between January 2013 and January 2015.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-2652504509

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.